• 1
    National Institutes of Health (NIH) Consensus Development Panel 2000 Osteoporosis prevention, diagnosis, and therapy, NIH consensus statement online March 27-29, 2000; Available at: Accessed August 11.
  • 2
    Meunier PJ, Boivin G 1997 Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone 21:373377.
  • 3
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:15311538.
  • 4
    Parfitt AM 1992 Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13(Suppl 2):S41S47.
  • 5
    Kleerekoper M, Villanueva AR, Stanciu J, Sudhaker Rao DS, Parfitt AM 1985 The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594597.
  • 6
    Lips P, Courpron P, Meunier PJ 1978 Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age. Calcif Tissue Res 26:1317.
  • 7
    Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL 1997 Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:10831091.
  • 8
    Eventov I, Frisch B, Cohen Z, Hammel I 1991 Osteopenia, hematopoiesis, and bone remodelling in iliac crest and femoral biopsies: A prospective study of 102 cases of femoral neck fractures. Bone 12:16.
  • 9
    Dunstan CR, Somers NM, Evans RA 1993 Osteocyte death and hip fracture. Calcif Tissue Int. 53(Suppl 1):S113S116.
  • 10
    Mori S, Harruff R, Ambrosius W, Burr DB 1997 Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 21:521526.
  • 11
    Compston JE, Mellish RW, Garrahan NJ 1987 Age-related changes in iliac crest trabecular microanatomic bone structure in man. Bone 8:289292.
  • 12
    Deng HW, Chen WM, Conway T, Zhou Y, Davies KM, Stegman MR, Deng H, Recker RR 2000 Determination of bone mineral density of the hip and spine in human pedigrees by genetic and life-style factors. Genet Epidemiol 19:160177.
  • 13
    Deng HW, Stegman MR, Davies KM, Conway T, Recker RR 1999 Genetic determination of variation and covariation of peak bone mass at the hip and spine. J Clin Densitom 2:251263.
  • 14
    Deng H, Li J, Mahaney MC, Theresa C, Davies MK, Williams JT, Chen W, Li J, Deng H, Recker RR 2000 Are genes found important for BMD variation relevant to susceptibility to osteoporotic fractures? J Bone Miner Res 15:S1;S162.
  • 15
    Deng H-W, Chen W-M, Recker S, Stegman MR, Li J-L, Davies KM, Zhou Y, Deng H, Heaney R, Recker RR 2000 Genetic determination of Colles' fracture and differential bone mass in women with and without Colles' fracture. J Bone Miner Res 15:12431252.
  • 16
    Turner CH, Hsieh Y-F, Müller R, Bouxsein ML, Baylink DJ, Rosen CJ, Grynpas MD, Donahue LR, Beamer WG 2000 Genetic regulation of cortical and trabecular bone strength and microstructure in inbred strains of mice. J Bone Miner Res 15:11261131.
  • 17
    Turner CH, Hsieh Y-F, Müller R, Bouxsein ML, Rosen CJ, McCrann ME, Donahue LR, Beamer WG 2001 Variation in bone biomechanical properties, microstructure, and density in BXH recombinant inbred mice. J Bone Miner Res 16:206213.
  • 18
    Faulkner KG, McClung M, Cummings SR 1994 Automated evaluation of hip axis length for predicting hip fracture. J Bone Miner Res 9:10651070.
  • 19
    Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919923.
  • 20
    Delmas PD 2000 How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone. 27:13.
  • 21
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:15351541.
  • 22
    Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C 2000 Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 15:11131118.
  • 23
    Minne HW, Pfeifer M, Begerow B, Nachtigall D, Hansen C 2000 Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalisation of blood pressure: A prospective, randomized, and double-blind study. Osteoporos Int 11(Suppl 2):S115.
  • 24
    Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:25772586.
  • 25
    Turner CH, Sato M, Bryant HU 1994 Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135:20012005.
  • 26
    Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231236.
  • 27
    Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, Wilson MC, Richardson WS for the Evidence-Based Medicine Working Group 2000 Users' guides to the medical literature: XXV. Evidence-based medicine: Principles for applying the users' guides to patient care. JAMA 284:12901296.
  • 28
    Cummings SR, Black DM, Pearson J, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix 2001 A for the Fracture Intervention Trial Research Group. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (in press)
  • 29
    Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III 1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802809.
  • 30
    Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, Leboff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D for the PROOF study group 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267276.
  • 31
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637645.
  • 32
    Harris ST, Watts NB, Genant HK, Mckeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282:13441352.
  • 33
    Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:8391.
  • 34
    Watts N, Roux C, Genant H, Adami S, Hangartner T, Miller P, Sorensen O, Hooper M, Ethgen D, Valent D 1999 Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis. J Bone Miner Res 14:S1;S136.
  • 35
    Heaney RP 1993 Is there a role for bone quality in fragility fractures? Calcif Tissue Int 53(Suppl 1):S3S6.
  • 36
    Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646650.
  • 37
    Huja SS, Katona TR, Burr DB, Garetto LP, Roberts WE 1999 Microdamage adjacent to endosseous implants. Bone 25:646650 217–222.
  • 38
    Hirano T, Burr DB, Cain RL, Hock JM 2000 Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 66:456460.
  • 39
    Oxlund H, Barckman M, Ørtoft G, Andreassen TT 1995 Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17(Suppl):365S371S.
  • 40
    Oxlund H, Mosekilde L, Ørtoft G 1996 Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone 19:479484.
  • 41
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:16931700.
  • 42
    Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C 1988 Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:12681274.
  • 43
    Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F 1989 A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10:313320.
  • 44
    Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:19.
  • 45
    Vedi S, Compston JE 1996 The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women. Bone 19:535539.
  • 46
    Holland EF, Chow JW, Studd JW, Leather AT, Chambers TJ 1994 Histomorphometric changes in the skeleton of postmenopausal women with low bone mineral density treated with percutaneous estradiol implants. Obstet Gynecol 83:387391.
  • 47
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:14751480.
  • 48
    Macdonald B, Van Rietbergen B, Newitt D, Harris ST, Genant H, Chesnut C, Majumdar S 2000 The effect of idoxifene on structural and mechanical properties of bone assessed by non invasive techniques in postmenopausal women. J Bone Miner Res 15:S1;S198.
  • 49
    Dempster DW, Cosman F, Kurland E, Müller R, Nieves J, Woelfert L, Shane E, Plavetic K, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:18461853.
  • 50
    Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157165.
  • 51
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687694.
  • 52
    Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone. 27:1320.
  • 53
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:13631374.
  • 54
    Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, Nakamaru Y, Hiroi E, Hiura K, Kameda A, Yang NN, Hakeda Y, Kumegawa M 1997 Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186:489495.
  • 55
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:14781487.
  • 56
    Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, Digregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719730.
  • 57
    Deng HW, Li J, Li JL, Johnson M, Gong G, Recker RR 1999 Association of VDR and estrogen receptor genotypes with bone mass in postmenopausal Caucasian women: Different conclusions with different analyses and the implications. Osteoporos Int 9:499507.
  • 58
    Link TM, Majumdar S, Augat P, Lin JC, Newitt D, Lu Y, Lane NE, Genant HK 1998 In vivo high resolution MRI of the calcaneus: Differences in trabecular structure in osteoporosis patients. J Bone Miner Res 13:11751182.
  • 59
    Kneissel M, Boyde A, Gasser JA 2001 Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28:237250.
  • 60
    Chesnut C, Shields A, Pitzel P, Lind T, Kaiser J, Cather J, Kriegman A, Mindeholm L 1999 How do antiresorptive osteoporosis therapies reduce fracture in the absence of robust effects on bone mineral density (BMD) and remodeling? The QUEST (Qualitative Effects of Salmon-Calcitonin Treatment) Study. J Bone Miner Res 14:S1;S515.
  • 61
    Chesnut C, Majumdar S, Newitt D, Shields A, Pitzel P, Lind T, Kaiser J, Cather J, Scott R, Schmeer S 1999 The in vitro and in vivo effects of nasal spray salmon-calcitonin (NS-CT) on bone quality: The QUEST (Qualitative Effects of Salmon-Calcitonin Treatment) Study, baseline parameters. J Bone Miner Res 14:S1;S516.
  • 62
    Glüer C-C 1999 Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14:19521962.
  • 63
    Bonnick SL 1998 Bone Densitometry in Clinical Practice: Application and Interpretation, Humana Press, Inc., Totowa, NJ, USA.
  • 64
    Ray NF, Chan JK, Thamer M, Melton LJ III 1997 Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 12:2435.